Imsidolimab, an IL-36 Receptor Antagonist, Was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients With Generalized Pustular Psoriasis **Results From the Phase 3 Trials, GEMINI-1 and GEMINI-2**

Adam Reich¹, Hervé Bachelez², Evelyn Wen Yee Yap³, Murat Borlu⁴, Panlop Chakkavittumrong⁵, Jacek C. Szepietowski⁶, Mohamed Denguezli⁷, Anne Severtson⁸, Bruce Randazzo⁸, Priya Raina⁸, Khalil Saikali⁸, Martin Dahl⁸, Paul Lizzul⁸, Johann E. Gudjonsson⁹

¹Medical College of Rzeszow University, Rzeszow, Poland; ²Saint-Louis University Hospital, Paris, France; ³Hospital Pakar Sultanah Fatimah Muar, Johor, Malaysia; ⁴Erciyes University, Kayseri, Turkey; ⁵Thammasat University, Pathum Thani, Thailand; ⁶Wroclaw Medical University, Wroclaw, Poland; ⁷Farhat Hached Hospital, Sousse University, Tunisia; ⁸AnaptysBio, San Diego, CA, USA; ⁹University of Michigan, Ann Arbor, MI, USA

BACKGROUND & INTRODUCTION

- Generalized pustular psoriasis (GPP) is a chronic, systemic, inflammatory skin disease that can be severe, debilitating, and life threatening
- GPP is characterized by intermittent flares with eruptions of sterile pustules on erythematous skin. Systemic features such as high fever, general malaise, leukocytosis, and elevated C-reactive protein also occur; extracutaneous organ involvement can lead to substantial morbidity and mortality¹
- Loss of function mutations in the gene encoding IL-36 receptor antagonist were identified in a subset of patients with GPP, suggesting that IL-36 is a key cytokine in the pathogenesis of GPP²
- Imsidolimab is an investigational IgG4 antibody that specifically binds to the IL-36 receptor and antagonizes IL-36 signaling, reducing the functional activity of IL-36 cytokines
- In the Phase 2 GALLOP trial (NCT03619902), imsidolimab was well tolerated and demonstrated rapid and sustained improvements in symptoms and pustular eruptions in patients with GPP flare,³ providing supporting evidence to advance to Phase 3 studies
- The results of 2 completed Phase 3 trials, GEMINI-1 (NCT05352893) and GEMINI-2 (NCT05366855), of imsidolimab in patients with GPP are reported here

GEMINI-1

- Randomized, double-blind, placebo (PBO)-controlled, global study evaluated the safety and efficacy of an induction dose of imsidolimab 750mg or 300mg IV versus PBO for treatment of GPP flare
- Adults, 18 to 80 years of age, with clinically confirmed diagnosis of GPP flare of moderate to severe intensity defined as:

METHODS

- Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) score ≥ 3
- Pustulation Rating Scale (PRS) score ≥ 3
- Active flare and pustules $\geq 5\%$ of body surface area (BSA)
- Patients were randomized (1:1:1) to a single dose of imsidolimab 750mg IV, imsidolimab 300mg IV, or PBO IV and followed until they rolled over to GEMINI-2 (Figure 1)
- Primary endpoint: GPPPGA score of clear (0) or almost clear (1) collectively across all GPP disease attributes (pustulation, erythema, scaling) at Week 4
- Key secondary endpoint: PRS of 0 or 1 at Week 1 **GEMINI-2**
- Long-term extension of GEMINI-1: randomized, double-blind, PBO-controlled study of imsidolimab 200mg SC every 4 weeks vs PBO for maintenance and prevention or delaying recurrence of a re-flare (GPPPGA \geq 3) relative to a single IV induction dose (**Figure 1**)

GEMINI-1 and GEMINI-2 Study Designs

RESULTS




Figure 1. Study design and patient numbers per groups in GEMINI-1 and GEMINI-2

- Patients in GEMINI-1 could rollover into GEMINI-2 if they were a responder or partial responder at Week 4. Patients who had no improvement or worsened (nonresponder) between Week 1 and Week 4 could rollover into GEMINI-2 to receive rescue therapy
- Treatment in GEMINI-2 was based on their responder status in GEMINI-1 (Figure 1)
- Patients were followed for at least 24 weeks and up to maximum of 92 weeks
- Topline PBO-controlled data from the responders re-randomized in GEMINI-2 and observational data from the PBO non-responders who received imsidolimab 750mg IV as rescue therapy and 200mg SC for maintenance in GEMINI-2 are presented

Responder Definitions

- Responder: Completed Week 4 of GEMINI-1 with GPPPGA score of 0 or 1 collectively across all GPP disease attributes (pustulation, erythema, scaling)
- Partial responder: Completed Week 4 of GEMINI-1 but did not have GPPPGA score of 0 or 1
- Non-responder: No improvement or worsened

GEMINI-1: Imsidolimab 750mg and 300mg IV were Effective in the Treatment of GPP Flare in GEMINI-1 & in Crossover PBO Patients in GEMINI-2 (750mg IV)

> **Primary Endpoint GPPPGA 0/1** at Week 4

Key Secondary Endpoint PRS 0/1 at Week 1

GEMINI-1: Rapid and Clinically Meaningful Improvement of GPP was Obtained With Single Dose Imsidolimab 750mg IV and 300mg IV

GPPPGA 0/1 Response Over Time




Figure 2. Percentage of patients achieving GPPPGA 0/1 at Week 4 and PRS 0/1 at Week 1 in GEMINI-1 after a single IV dose of imsidolimab 750mg, 300mg, or PBO


Safety and Tolerability

GEMINI-1

- Treatment-emergent adverse events (TEAE) were similar across treatment groups
- No SAEs or severe AEs in imsidolimab-treated patients
- No cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or Guillain-Barre Syndrome (GBS)
- Low incidence and no elevation of infections vs. placebo
- No infusion reactions reported
- Of the 30 patients treated with imsidolimab, 1 treated with 750 mg (3%) had detectable non-neutralizing anti-drug antibodies (ADA)

GEMINI-2

- TEAEs were similar in imsidolimab and PBO groups
- No SAEs led to study treatment discontinuation/withdrawal




Significantly more patients who received imsidolimab 750mg IV in GEMINI-1 achieved the primary endpoint of GPPPGA 0/1 at Week 4 vs. PBO (Figure 3)

Figure 3. Percentage of patients who received a single dose of imsidolimab 750mg IV, imsidolimab 300mg IV, or PBO in GEMINI-1 and achieved GPPPGA score of 0/1. The dashed line is the percentage of PBO non-responders who crossed over to GEMINI-2 rescued with imsidolimab 750mg IV (observational data)

GEMINI-2: Imsidolimab 200mg SC Every 4 Weeks Maintained Response & Prevented GPP Re-flaring Regardless of GEMINI-1 Imsidolimab Dose

- Imsidolimab (n=8): 100% maintained a GPPPGA score of 0/1 and 0 flared
- PBO (n=8): 25% maintained a GPPPGA score of 0/1 and 62.5% flared $(GPPPGA \geq 3)$
- Imsidolimab significantly maintained GPPPGA response regardless of GEMINI-1 dose (Figure 4)
- PBO crossover patients who received imsidolimab 750mg IV/200mg SC in GEMINI-2 (n=9): 77.8% maintained remission for at least 24 weeks (observational data)



Similar to GEMINI-1: No DRESS or GBS, low incidence and no elevation of infections vs placebo, no infusion reaction, and uncommon ADA

Figure 4. Kaplan-Meier curve of time to loss of response with imsidolimab 200mg SC (shown by dose of imsidolimab received in GEMINI-1) and PBO every 4 weeks

CONCLUSIONS

- Rapid and clinically meaningful improvement of GPP was obtained with single IV doses of imsidolimab 300mg and 750mg
- Regardless of the single IV dose received in GEMINI-1 (300 mg or 750 mg), maintenance dosing with every 4-week 200mg SC imsidolimab maintained clearance of GPP and prevented flares during at least 24 weeks of follow-up
- These findings from a randomized, double-blind, placebo-controlled trial were further supported with observational data from patients receiving open-label imsidolimab

ACKNOWLEDGEMENTS

- 1. GEMINI-1 and GEMINI-2 trials were supported by Anaptys
- 2. Disclosures: AR, HB, EWYY, MB, PC, JCS, MD, JEG were investigators for GEMINI-1 and GEMINI-2. AR, HB, & JEG are advisors for Anaptys. AS, BR, PR, KS, MD, and PL are employees and stockholders of Anaptys. Other disclosures available upon request
- 3. Medical writing support was provided by Susan Sutch, PharmD and funded by Anaptys
- 4. Anaptys is grateful to all investigators and to the patients and their caregivers for participation in these studies

Overall, ADAs were non-neutralizing and detection was uncommon • Imsidolimab represents a promising therapeutic option for patients with GPP

• Across the trials, imsidolimab administered IV or SC was well tolerated

- Low incidence and no elevation of infections vs placebo



- 1. Gooderham MJ, et al. Expert Rev Clin Immunol 2019;15:907-19.
- 2. Marrakchi S, et al. N Engl J Med 2011;365:620-28.
- 3. Warren RB, et al. Br J Dermatol 2023;189:161-69.

- No infusion reactions were reported



Presented at European Academy of Dermatology & Venereology, Amsterdam, The Netherlands, 25-28 September 2024